Spores remain dormant for centuries, waiting for the world to become habitable again.
Over millions of years, certain bacteria evolved the ability to collapse into near-indestructible spores and wait out catastrophe — a trick that bioengineers at Tufts University are now learning to redirect toward human ends. By systematically mapping the proteins that coat these dormant shells, researchers have expanded the number of viable engineering targets from twelve to thirty-three, opening a far wider design space for vaccines, environmental sensors, and plastic-degrading enzymes. The work is a reminder that nature's oldest survival strategies often contain the seeds of our newest technologies — and that the distance between a bacterium waiting out a drought and a drug reaching a remote village may be shorter than we imagined.
- A narrow toolkit of only twelve spore coat proteins had quietly constrained an entire field of bioengineering for years, limiting what could be built and who could be reached.
- Tufts researchers broke that ceiling by identifying thirty-three viable protein fusion targets — nearly triple the previous count — dramatically widening what engineered spores can carry and do.
- Concrete possibilities are already taking shape: oral vaccines that need no refrigeration, biological sensors that glow in the presence of toxins, and spore-bound enzymes that dissolve PET plastic four times more efficiently than prior candidates.
- A critical safety threshold looms — engineered spores must be prevented from germinating in the wild, and researchers are developing a five-gene deletion protocol to keep them permanently inert.
- A spinout company, Caravel Bio, is already moving the technology toward market, signaling that the field is transitioning from proof-of-concept to the harder work of real-world deployment.
Bacteria have spent millions of years perfecting a survival strategy: when conditions turn hostile, certain species collapse inward and harden into spores — dense, protein-coated spheres that can lie dormant for centuries. Bioengineers have long recognized these structures as natural platforms for useful products. Fuse a therapeutic protein to a spore's outer coat, and you have something that needs no refrigeration, survives harsh conditions, and can be shipped anywhere.
The technology, however, had been working with a limited palette. Only about a dozen of the nearly fifty proteins composing a spore's shell had been explored as fusion targets. A team at Tufts University, led by associate professor Nik Nair, changed that by systematically testing the full range of coat proteins and identifying thirty-three viable candidates — nearly triple the previous number. The findings appear in JACS Au.
The applications are already becoming tangible. Engineered spores could deliver oral vaccines without a cold chain, a meaningful advantage for remote regions. They could be designed to fluoresce in the presence of specific toxins, functioning as biological sensors in contaminated environments. The lab's most striking proof of concept involved plastic degradation: fusing enzymes onto spore proteins to break down PET, the hard plastic in water bottles and car parts. One small assembly protein, SscA, yielded four times more enzymatic activity than any other candidate in solution, while a different protein, CotY, proved more effective on solid plastic. The researchers even envisioned stacking multiple fusion products on a single spore to create a multi-step breakdown process.
Before these spores can be released at scale, a safety question must be resolved: what stops them from waking up and replicating in the environment? Nair noted that deleting five specific genes can ensure spores never germinate, remaining inert indefinitely. That genetic lock will be essential for commercial deployment. A startup called Caravel Bio, founded by former lab graduate student Trevor Chappell, is already advancing the technology toward market.
Spore engineering is still early, with most products in development and none yet widely available. But the sudden expansion of the protein toolkit suggests the field is accelerating — and the distance between a laboratory bench and a vaccine reaching a remote village, or an enzyme dissolving a plastic bottle, may be closing faster than expected.
Bacteria have a survival trick that evolution perfected over millions of years. When conditions turn hostile—extreme heat, drought, starvation, chemical assault—certain bacterial species collapse inward and harden into spores, dense protein-coated spheres that can lie dormant for centuries, waiting for the world to become habitable again. This extraordinary resilience has caught the attention of bioengineers, who see in these spores a natural platform for manufacturing useful things: drugs, enzymes, sensors, catalysts. Fuse a therapeutic protein to the spore's outer coat, and you have a product that needs no refrigeration, survives harsh conditions, and can be shipped anywhere.
The technology is promising but young. Until recently, researchers had only explored about a dozen of the nearly fifty proteins that make up a spore's protective shell as potential fusion targets. That narrow toolkit limited what could be built. Now a team at Tufts University, led by Nik Nair, an associate professor of chemical and biological engineering, has expanded that list dramatically. By systematically testing the spore coat proteins, Nair and his colleagues identified as many as thirty-three candidates for fusion—nearly triple the previous number. The work appears in the journal JACS Au and suggests that the range of bioengineered spore products could be far wider than anyone expected.
The applications are already becoming concrete. Engineered spores could deliver vaccines orally, passing through the gastrointestinal tract to trigger immune responses without a needle or a cold chain—a significant advantage for remote regions. They could be designed to fluoresce in the presence of specific toxins, turning them into biological sensors for contaminated environments. But perhaps the most tangible proof of concept came from the lab's work on plastic degradation. Nair's team fused enzymes onto spore proteins that can break down polyethylene terephthalate, the hard plastic found in water bottles and car parts. When they tested their expanded protein list, they found that a small assembly protein called SscA worked best, yielding four times more enzymatic activity than any other fusion candidate. On solid plastic itself, a different protein, CotY, proved more effective, likely because it sits more exposed on the spore's surface. The researchers even imagined combining multiple fusion products in a single spore to create a multi-step process: break down the plastic, then metabolize the fragments into something harmless.
But before engineered spores can be deployed at scale, a critical safety question must be answered. What prevents these dormant bacteria from waking up and replicating once they're released into the environment? Nair emphasized that the science here is well understood. By deleting five specific genes, researchers can ensure spores never germinate, remaining inert indefinitely. This genetic lock will be essential before widespread commercial use. The work is already moving toward the marketplace. A startup called Caravel Bio, founded by Trevor Nicks, a former graduate student in Nair's lab and co-author of the study, is developing the technology further. Todd Chappell, a former postdoctoral researcher, led the experimental work.
Spore engineering remains in its early stages, with most products still in development and none yet widely available. But the expansion of the protein toolkit suggests the field is accelerating. What was once a narrow set of possibilities—a dozen proteins, a handful of applications—has suddenly become something larger and more flexible. The next phase will be watching whether these engineered spores can move from the laboratory into real-world use: vaccines reaching remote villages, enzymes dissolving plastic waste, sensors detecting invisible threats. The foundation is being laid. The safety guardrails are being designed. The question now is how quickly the technology can mature.
Citações Notáveis
Spore engineering is still an emerging technology. Most products are in the development stage and are not ready for widespread commercial application. We are hopeful that expanding the target list for fusion can speed up this process.— Nik Nair, associate professor of chemical and biological engineering at Tufts
If we delete five specific genes, they'll never germinate and always remain spores. Product safety will be a critical part of introducing spores to widespread applications.— Nik Nair
A Conversa do Hearth Outra perspectiva sobre a história
Why does the dormancy of bacterial spores matter so much for this work?
Because it solves a distribution problem that has always plagued medicine and biotechnology. A vaccine that needs refrigeration can't reach a village without electricity. A plastic-degrading enzyme that's unstable in heat can't work in a landfill. Spores are already built to survive anything. We're just borrowing that property.
So you're essentially hijacking evolution's solution to a different problem.
Exactly. Bacteria evolved spores to survive starvation and poison. We're saying: what if we glue something useful to the outside and let that same durability protect our product instead?
The jump from twelve proteins to thirty-three seems huge. Why was the number so limited before?
Testing is slow and expensive. You have to fuse each protein individually, grow the spores, measure the results. Twelve was what people had gotten around to. Nair's team did the systematic work to find thirty-three. It's not that the others were impossible—they just hadn't been tried.
What worries you most about this technology reaching the real world?
The reactivation question keeps me up. You're releasing billions of engineered spores into an environment. If even a tiny fraction somehow germinate, you've released a new organism into the wild. The gene-deletion approach sounds solid, but it has to be foolproof. There's no margin for error.
Is there a timeline for when we might actually see these products?
Not yet. Most things in biotech take longer than anyone hopes. But the fact that a startup is already spinning out from this work suggests people believe it's real enough to bet money on. That's usually a good sign.